Acetazolamide Trial in Normal Pressure Hydrocephalus
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
A pharmacological treatment to patients with normal pressure hydrocephalus (NPH) is missing.
The aim is to investigate if acetazolamide given to patients with NPH improves gait function
and study the pathophysiological mechanisms leading to reduced symptoms.
Patients will be randomized to acetazolamide or placebo and duration of treatment will be
from diagnosis to the day of shunt surgery. Target dose is 500 mg/day. Study design is a
double-blind randomized controlled trial and the plan is to include 42-50 patients. The study
is investigator-initiated without financial sponsorship from the industry.
Phase:
Phase 2
Details
Lead Sponsor:
Johan Virhammar
Collaborators:
Swedish Society for Medical Research Uppsala University